The agenda will cover Esperion’s bempedoic acid franchise, its completed and ongoing Phase 3 studies, the scientific validation for its approach, additional context into the regulatory process, and insights from the provider, patient, and payer perspectives. The program will feature presentations from key opinion leaders, independent advisors, and a member of the Esperion Lipid Management Team, including:
- Jorge Plutzky, MD – Director, Cardiovascular Medicine, Brigham and Women’s Hospital
- James Underberg, MD – Clinical Assistant Professor, Department of Medicine, NYU Langone
- Brian Ference, MD, MPhil, MSc, FACC – Director of Research in Translational Therapeutics, University of Cambridge
- Steven Nissen, MD, MACC – Chairman, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic
- John Jenkins, MD – Principal, Drug and Biological Products, Greenleaf Health; formerly Director of the Office of New Drugs in CDER (Center for Drug Evaluation and Research) at FDA
- Mark Glickman – Chief Commercial Officer, Esperion
- Jane Barlow, MD, MPH, MBA, Executive Vice President and Chief Clinical Officer, Real Endpoints
The live event will be videocast simultaneously and accessible through the Events & Presentations page of the Esperion website at investor.esperion.com. Access to the event replay will be available approximately two hours after completion and will be archived on the Company's website for approximately 90 days.